Conferences
ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
ESH 2016 - 3rd International Conference on Multiple Myeloma
7 - 9 Oct 2016
TBC, Milan, Italy
Outcome of multiple myeloma has dramatically improved over the last years with the introduction of novel agents. These agents have not only improved the complete remission rates, but they have resulted in tangible improvements in survival. At present, numerous questions surrounding the transplant and non-transplant settings remain, such as the role for prolonged/maintenance therapy, the role of high-dose therapy itself at the era of novel agents, as well as other practical questions regarding the optimization of the different steps of myeloma treatment algorithms. This educational meeting aims to address the latest developments in the field, as part of our quest for more effective and better-tolerated therapies, and improved understanding of the physiopathology of the disease. A large number of prestigious speakers will attend and deliver keynote lectures.
Upon completion of this CME activity, participants should be able to:
-
Acquire insight into the current diagnostic process of multiple myeloma, staging system, and risk stratification.
-
Evaluate the relevance of molecular diagnostics and minimal residual disease assessment, and their relevance for clinical management decisions.
-
Learn about treatment state of the art, and understand some of the critical clinical management issues in the treatment of young adults and patients of older age with fit or frail conditions.
-
Get insight into developmental therapeutics of multiple myeloma, Waldestrom macroglobulinemia and amyloidosis including knowledge about mechanisms of action of novel therapeutic compounds, the current status of development of various targeted drugs and their promises for future clinical applications.
Overcoming painful bone disease in myeloma
Dr Nicola Giuliani - University of Parma, Parma, Italy
History and progress of CD38 in myeloma
Dr Fabio Malavasi - University of Turin, Turin, Italy
Maintenance therapy in young myeloma patients beneficial after autologous stem c...
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
Better doctor-patient communication needed to improve myeloma outcomes
Dr Karthik Ramasamy - Oxford University Hospital, Oxford, UK
History of antiangiogenic drugs in multiple myeloma, starting with thalidomide
Dr Jens Hillengaß - UniversitätsKlinikum Heidelberg, Heidelberg, Germany
Elderly patients should be treated based on biological age, not chronological
Prof Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienn...
Cancer or amyloidosis?
Dr Giovanni Palladini - Director, Amyloidosis Research and Treatment Center, Pav...
Monoclonal antibodies in multiple myeloma
Dr Phillippe Moreau - University Hospital of Nantes, Nantes, France
How can we make the best decisions for health whilst considering cost?
Dr Andrea Manca - University of York, York, UK
Preemptively treating patients most at risk of progression to myeloma
Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain
Drug combos with daratumumab likely to become standard of care in myeloma
Dr Niels Van De Donk - VU University Medical Center, Amsterdam, Holland
Overview of the CD38 antibody in multiple myeloma
Dr Torben Plesner - Vejle Hospital, Vejle, Denmark
New drugs and combinations in haematological cancers improve complete remission ...
Dr Paolo Corradini - University of Milan, Milan, Italy
Benefits and problems of allogeneic stem cell transplantation as multiple myelom...
Prof Nicolaus Kröger - University Hospital Hamburg, Hamburg, Germany